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, EARL Y reports on the use of FK 506 after kidney 
, transplantation emphasized the ability to stop pred-
nisone in a significant percentage of successfully trans-
planted patients. I •2 In addition, there was a relative free-
dom from antihypertensive agents and a tendency toward 
low serum cholesterol levels. This report will summarize 
our experience to date with FK 506 in renal transplantation 
and will compare the results with a nearly concurrent 
group of patients treated with cyclosporine (CyA)-based 
MATERIALS AND METHODS 
Between March 27, 1989, the date of the first kidney transplant 
under FK S06 immunosuppression. and May I, 1991.464 kidney 
transplantations were performed at the U Diversity of Pittsburgh. 
Of these 28 were in patients who had received concomitant or 
previous liver transplants. and these were the only exclusions 
from the analysis. Of the 436 transplants in 425 patients. 196 
received Cy A-based immunosuppression; over 80% of this group 
received azathioprine as well (Table I). Some 240 cases were 
treated with FK S06 and steroids. The mean recipient age was 39.S 
± 14.9 years; 44 (10.1%) of the cases were performed in patients 
over 60 years of age. and 31 (7.1%) of the transplants were to 
children. Sixty 03.7%) of the cases involved black recipients. 
There was a significantly higher incidence of retransplantation in 
the FK S06 grouJ>-Over 30% of the FK S06 cases were to patients 
Table 1. Recipient and Donor Charac:tertatlcs 
eyA FK506 Total 
No. Patients 191 234 425 
No. Transplants 196 240 436 
Mean age 38.2 :t 15.0 Y 40.5 ± 14.7y 39.5 :t 14.9 Y 
Pediatric cases 17 (8.7%) 14 (5.8%) 31 (7.1%) 
Recipient age >60 y 15 (7.7%) 29 (12.1%) 44 (10.1%) 
Black recipients 34 (17.3%) 26 (10.8%) 60 (13.7%) 
*Retransptantation 38 (19.4%) 76 (31.7%) 114 (26.1%) 
PRA >10% 45 (22.0%) 68 (28.0%) 113 (26.0%) 
PRA >40% 26 (13.0%) 41 (17.0"10) 67 (15.4%) 
Cadaver 168 (85.7%) 228 (95.0"10) 396(90.8%) 
tUving donor 28 (14.3%) 12 (5.0"10) 40(9.2%) 
Donor age 32.9 ± 16.4y 34.8:t 16.7 Y 34.0 ± 16.6y 
Cold ischemia time 37.0:t 11.2 h 35.9 ± 10.1 h 36.3 ± 10.6 h 
Pediatric en bloc 28 (16.7%) 45 (19.7%) 73 (18.4%) 
'p< ,005. 
tp< .02. 
undergoing their second to fifth transplant, whereas just under 
20% of the Cy A cases were retransplants (P < .OOS). Over 25% of 
the transplants were to sensitized recipients. A higher percentage 
of living-donor cases were done under CyA-14.3% vs S% of the 
FK S06 cases (P < .02). 
The mean donor age was 34.0 ± 16.6 years; 73 (18.4%) of the 
cadaver transplants were with pediatric en bloc kidneys. The 
mean cold ischemia time was 36.3 ± 10.6 hours. HLA matches 
and mismatches revealed a small number of good matches. with 
less than 2% of cases being 6-antigen matches and nearly two-
thirds of cases having a 2-antigen match or less. 
There was thus no attempt to be particularly discriminating in 
either donor or recipient selection. The FK S06 cases were 
actually a higher-risk group than was the CyA group-more 
retransplants. fewer living donor cases, slightly more sensitized 
patients. and en bloc kidneys. This had the effect of subjecting FK 
506 to a rather stringent evaluation. 
FK S06 dosage has evolved toward decreasing amounts. From 
March 1989 until June 1990. 0.07S mglkg was infused intrave-
nously over 4 hours twice a day. From June 1990 until August 
1990. 0.15 mglkg per day was given as a continuous infusion over 
24 hours. Since August 1990, a continuous intravenous infusion of 
Table 2. Actuarial One-Year Survival 
CyA FK506 Total 
Patient survival 
All 94% 90% 92% 
Graft survival 
All 710/0 74% 76% 
Cadaveric 75% 73% 74% 
Uving donor 89% 1000/0 96% 
Creatinine 1.9:t 1.7mg/dL 2.1 ± 1.2 mgldL 
BUN 31.0 ± 17 mg/dL 36.0 ± 22 mgldL 
Uric Acid 7.2:t 2.6 mgldL 8.1 :!: 2.4. mgldL 
'Cholesterol 236 :t 59 mgldL 187:t 51 mgldL 
'p < .0001; aU others P ~ NS. 
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